|
Ticagrelor (trade name Brilinta in the US and Russia, Brilique and Possia in the EU) is a platelet aggregation inhibitor produced by AstraZeneca. The drug was approved for use in the European Union by the European Commission on December 3, 2010.〔(【引用サイトリンク】title=Assessment Report for Brilique )〕〔(European Public Assessment Report Possia )〕 The drug was approved by the US Food and Drug Administration on July 20, 2011.〔(【引用サイトリンク】title=FDA approves blood-thinning drug Brilinta to treat acute coronary syndromes )〕 Ticagrelor is an antagonist of the P2Y12 receptor. ==Medical uses== Ticagrelor is used for the prevention of thrombotic events (for example stroke or heart attack) in people with acute coronary syndrome or myocardial infarction with ST elevation. The drug is combined with acetylsalicylic acid unless the latter is contraindicated. There is no high quality evidence for the use of ticagrelor in non-ST elevation acute coronary syndrome. The FDA indication for tigagrelor is reduction of the rate of cardiovascular death, myocardial infarction (MI), and stroke in people with acute coronary syndrome or history of myocardial infarction. AHA/ACC Guidelines (09/2014) state: "It is reasonable to choose ticagrelor over clopidogrel for P2Y12 inhibition treatment in patients with NSTE-ACS treated with early invasive strategy and/or coronary stenting". 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「ticagrelor」の詳細全文を読む スポンサード リンク
|